EurekaMag.com logo
+ Translate

Investigation of the sequence of colonization and candidemia in nonneutropenic patients


, : Investigation of the sequence of colonization and candidemia in nonneutropenic patients. Journal of Clinical Microbiology 32(4): 975-980

Among neutropenic patients with hematologic malignancies, candidemia has been shown to arise typically from autoinfection after colonization. In patients without neutropenia, we examined the similarities of strains colonizing or infecting various body sites and those subsequently causing Candida bloodstream infections. Strain similarity was examined by karyotyping and restriction endonuclease analysis of genomic DNA (REAG) by using two restriction enzymes (SfiI and BssHII). The banding patterns of 42 isolates from 19 patients were independently evaluated in a blinded fashion by three observers. The interobserver reliability measured with a generalized kappa statistic was 0.59 for karyotyping, 0.84 for REAG with SfiI, and 0.88 for REAG with BssHII (P < 0.001 for each). REAG classified the initial colonizing or infecting isolate and subsequent blood isolates as identical in 16 patients (84%). The mean duration of colonization or infection prior to a positive blood culture was 5 and 23 days in patients infected with related and unrelated isolates, respectively (P = 0.14; 95% confidence interval = -14.5 to 50.5). Karyotyping results matched the REAG results for isolates from 14 of the 19 patients (74%). In patients infected with identical isolates, the initial isolate was most frequently recovered from the urine (n = 5) or vascular catheter tips (n = 4). In the five subjects with organisms showing disparate results between the methods, karyotyping revealed different banding patterns, whereas REAG suggested that the isolates were identical. Candida colonization or infection with an identical strain frequently precedes bloodstream infection in nonneutropenic patients. Future studies should evaluate whether patients at high risk for candidemia and who have vascular catheter or urine samples that are positive for a Candida on culture should be treated empirically.

(PDF 0-2 workdays service)

Accession: 002416952

PMID: 8027353

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Voss, A.; Hollis, R.J.; Wenzel, R.P.; Doebbeling, B.N., 1993: Investigation of the sequence of colonization and candidemia in non-immunocompromised patients. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 33(0): 131

Rex, J.H.; Pfaller, M.A.; Barry, A.L.; Nelson, P.W.; Webb, C.D., 1995: Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. The antifungal susceptibilities of 232 pathogenic blood stream Candida isolates collected during a recently completed trial comparing fluconazole (400 mg/day) with amphotericin B (0.5 mg/kg of body weight per day) as treatment for candidemia in th...

Cohen, Y.; Sadourny, F.; Gauzit, R.; Fosse, J.P.; Fraisse, F., 1998: Prognosis factors in candidemia in nonneutropenic critically-ill patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 491

Playford, E.Geoffrey.; Marriott, D.; Nguyen, Q.; Chen, S.; Ellis, D.; Slavin, M.; Sorrell, T.C., 2008: Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Objective: The objective of this study was to determine the clinical features associated with candidemia caused by non-<i>albicans Candida</i> spp. and with potentially fluconazole-resistant <i>Candida</i> spp. (<i>C....

Luzzati, R.; Lazzarini, L.; Amalfitano, G.; Soldani, F.; Vivenza, C.; Solbiati, M.; Concia, E., 1999: Risk factors for death in nonneutropenic patients with candidemia at a tertiary-care hospital. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 623

Grau, S.; Pozo, J.C.; Romá, E.; Salavert, M.; Barrueta, J.A.; Peral, C.; Rodriguez, I.; Rubio-Rodríguez, D.; Rubio-Terrés, C., 2015: Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients. To estimate the cost-effectiveness of three echinocandins (anidulafungin, caspofungin, and micafungin) and generic fluconazole in the treatment of nonneutropenic adult patients with candidemia and/or invasive candidiasis in intensive care units in...

Pai, M.P.; Turpin, R.S.; Garey, K.W., 2006: Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. The present study tested in vitro susceptibility of Candida bloodstream isolates to fluconazole to determine if the ratio of the fluconazole area under the concentration-time curve (AUC) or weight-normalized daily dose (dose(wn)) to MIC correlated...

Williams, A.H.; Moore, J.E., 1999: Multicenter study to evaluate the safety and efficacy of various doses of liposome-encapsulated nystatin in nonneutropenic patients with candidemia. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 567

Rex, J.H.; Pfaller, M.A.; Barry, A.L.; Nelson, P.W.; Webb, C.D., 1995: Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. The antifungal susceptibilities of 232 pathogenic bloodstream Candida isolates collected during a recently completed trial comparing fluconazole (400 mg/day) with amphotericin B (0.5 mg/kg of body weight per day) as treatment for candidemia in the...

Kullberg, B.J.; Vandewoude, K.; Aoun, M.; Jacobs, F.; Herbrecht, R.; Kujath, P., 1998: A double-blind, randomized, placebo-controlled phase II study of filgrastim in combination with fluconazole for treatment of invasive candidiasis and candidemia in nonneutropenic patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 479